Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

More articles from Endo V: Thyroid Cancer Update II

  • You have access
    Use of rhTSH or thyroid hormone withdrawal in the follow-up of thyroid cancer
    Knut Liepe and Marika Vereb
    Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 367;
  • You have access
    A serum predictor of Graves' disease recurrence following radioactive iodine therapy
    Russell Kosik, Andrea Tom and Jeffrey Tseng
    Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 368;
  • You have access
    Relationship among FDG uptake, thyroglobulin doubling time, and clinical behavior in postsurgical papillary thyroid cancer
    Kunihiro Nakada, Hiroki Sugie, Yasushi Furuta, Mutsuo Beniko, Keiichi Kamijo and Masayuki Sakurai
    Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 366;
  • You have access
    Significance of FDG-PET/PETCT for long-term survival in patients with Hurthle cell carcinoma of the thyroid (HCTC)
    Helmut Dittmann, Ingo Frank, Matthias Reimold and Roland Bares
    Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 363;
  • You have access
    Preablative stimulated thyroglobulin can predict the response to I-131 therapy for FDG-avid lymph nodes in thyroid papillary cancer patients
    Seong Young Kwon, Ari Chong, Sae-Ryung Kang, Sang-Geon Cho, Hee Jeong Park, Jahae Kim, Su Woong Yoo, Jung Joon Min, Ho-Chun Song and Hee-Seung Bom
    Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 365;
  • You have access
    Utility of delayed post-therapy whole body I-131 scan over early scan in patients with differentiated thyroid cancer: A prospective study
    Kanhaiyalal Agrawal, Anish Bhattacharya, Senthil Raja, Ashwani Sood and Bhagwant Mittal
    Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 364;
  • You have access
    Follow-up of patients with differentiated thyroid carcinoma and cervical lymph node metastases detected by SPECT/CT at first radioablation - A bicentric study
    Daniela Schmidt, Harun Ilhan, Peter Bartenstein and Torsten Kuwert
    Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 362;
SNMMI

© 2025 SNMMI

Powered by HighWire